# A Phase 2 Study of TRS005 in Patients With CD20-positive R/R DLBCL.

> **NCT06886139** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Zhejiang Teruisi Pharmaceutical Inc.** · enrollment: 139 (estimated)

## Conditions studied

- CD20-positive Diffuse Large B-Cell Lymphoma

## Interventions

- **DRUG:** TRS005

## Key facts

- **NCT ID:** NCT06886139
- **Lead sponsor:** Zhejiang Teruisi Pharmaceutical Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09
- **Primary completion:** 2027-01
- **Final completion:** 2027-09
- **Target enrollment:** 139 (ESTIMATED)
- **Last updated:** 2025-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06886139

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06886139, "A Phase 2 Study of TRS005 in Patients With CD20-positive R/R DLBCL.". Retrieved via AI Analytics 2026-09-16 from https://api.ai-analytics.org/clinical/NCT06886139. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*